Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model

Abstract Background Both modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in patients with pancreatic cancer, and are often used interchangeably as the standard of care. Preclinical studies often do not use these regimens, s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Abagail M. Delahoussaye, Joseph Abi Jaoude, Morgan Green, Tara N. Fujimoto, Jessica Molkentine, Carolina J. Garcia Garcia, Jason P. Gay, Ningping Feng, Joseph Marszalek, Natalie Fowlkes, Cullen M. Taniguchi
Fformat: Erthygl
Cyhoeddwyd: BMC 2022-02-01
Pynciau:
KPC mice
MFOLFIRINOX
Gemcitabine
Nab-paclitaxel
Pancreatic cancer
SBRT
Mynediad Ar-lein:https://doi.org/10.1186/s12885-022-09255-3
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

https://doi.org/10.1186/s12885-022-09255-3

Eitemau Tebyg